Tweet
March 23, 2021
DOI: 10.1056/NEJMc2101927
Jocelyn Keehner 1, Lucy E Horton 1, Michael A Pfeffer 2, Christopher A Longhurst 1, Robert T Schooley 1, Judith S Currier 3, Shira R Abeles 4, Francesca J Torriani 4
Data from phase 3 clinical trials of messenger RNA (mRNA) vaccines through November 2020 showed 94.1% efficacy for the prevention of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at 14 days after the second dose of the mRNA-1273 vaccine (Moderna)1 and 95% efficacy at 7 days after the second dose of the BNT162b2 vaccine (Pfizer).2 Since the results of these trials were published, a nationwide surge in coronavirus disease 2019 (Covid-19) has been noted, SARS-CoV-2 variants with increased infectivity have emerged, the Food and Drug Administration has granted emergency use authorization for these two mRNA vaccines, and vaccination has been initiated across the United States.
Since the start of the vaccination campaign, the development of Covid-19 has been reported in persons who have received one or both doses of vaccine.3 Both the University of California, San Diego (UCSD) and the University of California, Los Angeles (UCLA) health systems began to vaccinate health care workers on December 16, 2020.
DOI: 10.1056/NEJMc2101927
Jocelyn Keehner 1, Lucy E Horton 1, Michael A Pfeffer 2, Christopher A Longhurst 1, Robert T Schooley 1, Judith S Currier 3, Shira R Abeles 4, Francesca J Torriani 4
Data from phase 3 clinical trials of messenger RNA (mRNA) vaccines through November 2020 showed 94.1% efficacy for the prevention of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at 14 days after the second dose of the mRNA-1273 vaccine (Moderna)1 and 95% efficacy at 7 days after the second dose of the BNT162b2 vaccine (Pfizer).2 Since the results of these trials were published, a nationwide surge in coronavirus disease 2019 (Covid-19) has been noted, SARS-CoV-2 variants with increased infectivity have emerged, the Food and Drug Administration has granted emergency use authorization for these two mRNA vaccines, and vaccination has been initiated across the United States.
Since the start of the vaccination campaign, the development of Covid-19 has been reported in persons who have received one or both doses of vaccine.3 Both the University of California, San Diego (UCSD) and the University of California, Los Angeles (UCLA) health systems began to vaccinate health care workers on December 16, 2020.
